Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment

J Infect. 2022 Nov;85(5):e162-e163. doi: 10.1016/j.jinf.2022.07.014. Epub 2022 Jul 22.
No abstract available

Keywords: Cilgavimab; Mutations; Neutralizing monoclonal antibodies; SARS-CoV-2; Sequencing; Tixagevimab.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Drug Treatment*
  • Humans
  • Mutation
  • SARS-CoV-2* / genetics
  • Spike Glycoprotein, Coronavirus / genetics

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • tixagevimab
  • cilgavimab

Supplementary concepts

  • SARS-CoV-2 variants